載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$15.00
−US$0.49 · -3.16%
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
前收盤價
US$15.00
−US$0.49 · -3.16%
盤後
US$15.00
US$0.00 · 0.00%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
日內區間
目前US$15.00
52週區間
目前US$15.00
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
59
合理估值
情緒
52
多空交錯
風險
74
高風險
動能
28
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
日內區間
目前US$15.00
52週區間
目前US$15.00
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.4億 CNY | 5.16億 CNY | 5.37億 CNY | 5.63億 CNY | 5.08億 CNY |
| 銷貨成本 | 1.37億 CNY | 1.53億 CNY | 1.74億 CNY | 1.83億 CNY | 1.44億 CNY |
| 毛利 | 4.03億 CNY | 3.62億 CNY | 3.63億 CNY | 3.8億 CNY | 3.64億 CNY |
| 研究與開發 | 1.66億 CNY | 2.32億 CNY | 3.47億 CNY | 4.22億 CNY | 3.68億 CNY |
| 銷售、一般及管理費用 | 2.91億 CNY | 4.53億 CNY | 6.86億 CNY | 9.39億 CNY | 7.93億 CNY |
| 營業費用 | 4.58億 CNY | 7.2億 CNY | 10.33億 CNY | 13.6億 CNY | 11.61億 CNY |
| 利息收入 | 805.3萬 CNY | 1221.2萬 CNY | 1795.6萬 CNY | 945.8萬 CNY | 345.7萬 CNY |
| 利息支出 | 3萬 CNY | — | — | — | 153.6萬 CNY |
| 折舊和攤銷 | 2176.1萬 CNY | 5220萬 CNY | 1.33億 CNY | 1.24億 CNY | 4776.6萬 CNY |
| 營業利益 | −5484.5萬 CNY | −3.58億 CNY | −6.69億 CNY | −9.8億 CNY | −7.97億 CNY |
| 淨利 | −5534.6萬 CNY | −3.47億 CNY | −6.54億 CNY | −9.71億 CNY | −7.97億 CNY |
公司資料更新於 2026年10月13日。
報告持有此股票曝險的交易所交易基金。
Schwab International Equity ETFSCHF1906.77萬0.03%673.48億 USD0.03%US$27.13-0.51%
Schwab Fundamental International Large Company Index ETFFNDF1792.53萬0.07%253.12億 USD0.25%US$53.42-0.35%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1308.78萬0.03%406.96億 USD0.03%US$49.69-0.58%
State Street SPDR Portfolio Europe ETFSPEU35.23萬0.05%6.89億 USD0.07%US$53.02-0.21%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA25.9萬0.03%10.17億 USD0.30%US$97.45-0.24%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX20.23萬0.04%4.88億 USD0.20%US$53.12-0.38%
State Street SPDR MSCI World StrategicFactors ETFQWLD1.45萬0.01%1.76億 USD0.30%US$156.61+0.15%Schwab International Equity ETFSCHFSchwab Fundamental International Large Company Index ETFFNDFState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXState Street SPDR MSCI World StrategicFactors ETFQWLDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
